Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 38.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,095 shares of the medical research company’s stock after purchasing an additional 1,413 shares during the quarter. Blue Trust Inc.’s holdings in Amgen were worth $1,328,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the third quarter worth $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the third quarter worth $29,000. Matrix Trust Co acquired a new position in shares of Amgen in the third quarter worth $36,000. Livelsberger Financial Advisory acquired a new position in shares of Amgen in the third quarter worth $56,000. Finally, Icon Wealth Advisors LLC raised its holdings in shares of Amgen by 3,955.0% in the third quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock worth $56,000 after acquiring an additional 169,748 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $280.30 on Wednesday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The business has a 50-day moving average of $271.47 and a 200-day moving average of $305.51. The company has a market capitalization of $150.67 billion, a price-to-earnings ratio of 35.89, a PEG ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the firm posted $4.96 earnings per share. The company’s revenue was up 23.2% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.40%. Amgen’s payout ratio is 115.24%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. UBS Group cut their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, October 31st. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Wells Fargo & Company dropped their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Finally, Citigroup dropped their target price on Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.